Information Center
The XKH004 clinical trial for Ankylosing Spondylitis Phase II successfully concluded the investigator meeting.
Release time:
2021-12-08 12:12
On December 6, 2021, the XKH004 Phase II clinical trial investigator meeting organized by Xinkanghe Biopharmaceutical Company was successfully held in Shanghai.
The main participants of this meeting included Professor Xu Huji, the principal investigator from the leading unit Shanghai Changzheng Hospital, Associate Professor Zhou Ling, Director Wei from the research institution; researchers and personnel from various sub-centers; Xinkanghe's Chief Scientific Advisor Academician Dong Chen, CEO Mr. Wang Yaning, Vice President of Clinical Operations Mr. You Jianguo, and Vice President of Business Development Mr. Wu Xiaodong; Executive Vice President Ms. Song Hong from the contract research organization Stendham Group, Deputy General Manager Mr. Sun Tianjian from Shanghai Dengke, and the Stendham clinical operations and medical team.
Academician Dong Chen, Chief Scientist of Xinkanghe, gave a speech.
At the conference, Academician Dong Chen and Professor Xu Huji expressed their gratitude to the participating researchers and looked forward to the joint efforts of everyone to enable XKH004 to serve patients with ankylosing spondylitis as soon as possible.
During the formal reporting session of the conference, Mr. Wang Yaning, CEO of Xinkanghe, first gave a brief report on the basic situation, R&D status, and technical patents of Xinkanghe, focusing on the detailed explanation of the good effects of XKH004 in treating inflammatory diseases by simultaneously blocking IL-17A and IL-17F from a molecular mechanism perspective.
Associate Professor Zhou Ling from the Department of Rheumatology and Immunology at Shanghai Changzheng Hospital provided a detailed introduction to the XKH004 Phase II clinical trial protocol for researchers and personnel from various sub-centers at the conference. The researchers from each center also discussed the protocol, laying a good foundation for the success of the Phase II clinical trial.
Associate Professor Zhou Ling from the Department of Rheumatology and Immunology at Shanghai Changzheng Hospital gave a speech.
Subsequently, Mr. Fan Zhen, Senior Manager of the Customization Department of the contract research organization Stendham Group, and Mr. Cao Yong, Senior Manager of the Medical Affairs Department, provided a comprehensive explanation of the overall project operation plan, implementation points, and the research protocol scale usage plan during the Phase II clinical trial. Experts exchanged opinions on potential issues that may arise in the research, such as subject screening, implementation of inclusion and exclusion criteria, subject follow-up, and endpoint evaluation, and reached a consensus.
XKH004, Ankylosing Spondylitis, Phase II Clinical Trial
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com